A Rundown Of Real-Time Oncology Review Approvals And Pending Applications
Executive Summary
Seattle Genetics holds the award for fastest supplemental approval (11 days) and fastest new molecular entity approval (119 days) under the US FDA's RTOR program, according to the Pink Sheet's Performance Tracker.
You may also be interested in...
US FDA’s Three Review Speeds: Standard, Priority – And Oncology
FDA’s oncology review team likes to do things its own way – and at its own hyper fast pace.
US FDA’s Fastest Approvals Concentrate In Oncology, Infectious Disease
The agency’s quickest approvals include two in 2020 – Gilead’s Veklury and Seattle Genetics’ Tukysa – but two 1990s AIDS drugs are at the top of the list.
US FDA's Real-Time Oncology Review Times Coming Into Focus
With approval of AbbVie Inc./Genentech Inc.'s Venclexta as seventh under RTOR pilot, a roughly two-month median review time under the program could be taking shape.